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ABSTRACT The dopamine D4 receptor has lately attracted interest since it has been
hypothesized to be involved in the pathogenesis and pharmacotherapy of neuropsychiat-
ric diseases. The present study provides first in vivo evidence of dopamine D4 receptors in
primate brain using a [11C]benzo[g]quinoline, the novel radioligand [11C]SDZ GLC 756
([11C]GLC: in vitro dissociation constants at human receptor clones [nM]: 1.10 at D1; 0.40
at D2; 25 at D3; 0.18 at D4.2; 6.03 at D5). Dynamic positron emission tomography scans
were performed on healthy baboons (Papio hamadryas, n 5 3). Specific receptor binding
(SB) was calculated for striatum and neocortex (frontal, temporal, parietal, and occipital)
based on the differences between the regional and the cerebellar concentration of [11C].
Blockade of D1 and D5 receptors by SCH23390 (1.7 µmol/kg) diminished SB in the
striatum by 55 6 4% (mean 6 standard deviation, P , 0.05) and in the frontal cortex by
13 6 8% (P , 0.05) when compared to SB in the unblocked state (SBD1–D5). In the
presence of the dopamine antagonists SCH23390 (1.7 µmol/kg) and raclopride (5.7
µmol/kg)—which mask the D1, D2, D3, and D5 subtypes—SB of [11C]GLC to D4 receptors
(SBD4) was demonstrated in the striatum and all cortical regions of interest. In the
striatum, the ratio of SBD4/SBD1–D5 was 0.13 6 0.07. In the neocortex, SBD4/SBD1–D5 was
notably higher (0.77 60.29; mean of all cortical regions of interest). The widespread
distribution of dopamine D4 receptors suggests a basic functional role of this receptor
subtype in the modulation of cortical and subcortical neuronal activity. Synapse
30:341–350, 1998. r 1998 Wiley-Liss, Inc.
INTRODUCTION
Dopamine receptors are involved in the regulation of
human movement, motivation, and cognitive perfor-
mance, as well as in the pathophysiology of neuropsychi-
atric diseases (Jackson and Westlind-Danielsson, 1994;
Nestler, 1997; Seeman et al., 1993; Seeman, 1995;
Volkow et al., 1997; Williams and Goldman-Rakic,
1995). The physiological effects of dopamine on neuro-
transmission in mammalian brain are mediated by a
family of guanine nucleotide binding protein coupled
receptors (Dohlmann et al., 1991). Molecular cloning
has revealed the existence of five mammalian dopa-
mine receptor genes (D1–D5) which encode pharmaco-
logically distinct dopamine receptor subtypes (Civelli et
al., 1993; Gingrich and Caron, 1993; Jackson and
Westlind-Danielsson, 1994; Nestler, 1994; Seeman et
al., 1993; Seeman, 1995). Based on pharmacological
and structural criteria, these five subtypes have been
classified into two subfamilies of D1-like (D1, D5) and
D2-like (D2, D3, D4) dopamine receptors. D1-like and
D2-like receptors exert synergistic as well as opposite
effects at the molecular, cellular, and systems levels
(Civelli et al., 1993; Gingrich and Caron, 1993; Jackson
and Westlind-Danielsson, 1994; Nestler, 1994; Seeman,
1995). D1-like receptors stimulate adenylate cyclase
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and D2-like receptors act inhibitorily on the adenylate
cyclase and the cAMP pathway (Jackson and Westlind-
Danielsson, 1994; Nestler, 1994). The distribution of
cerebral D1-like and D2-like dopamine receptors has
been studied in primates and man in vitro (Lidow et al.,
1991; Hall et al., 1994) and—irrespective of their
corresponding subtypes—in vivo (Farde et al., 1985,
1997; Haldin et al., 1986; Volkow et al., 1997; et al.,
1998). Previous attempts to quantify the D4 receptor
density in vitro in postmortem human brains have led
to conflicting results (Kramer et al., 1997; Lahti et al.,
1996; Murray et al., 1995; Mrzljak et al., 1996; Rey-
nolds and Mason, 1995; Seeman et al., 1993, 1995).
One basic reason why the dopamine D4 receptor has
recently attracted such particular interest is because it
has been localized immunohistochemically on pyrami-
dal cells and on GABAergic nonpyramidal neurons in
primate brain (Mrzljak et al., 1996). The presence of D4
receptors in pyramidal cells has suggested a direct
inhibitory effect of dopamine on pyramidal cell activity,
while the stimulation of D4 receptors on nonpyramidal
GABAergic neurons has been related to a disruption of
the feedforward inhibition of GABAergic neurons on
pyramidal cells (Mrzljak et al., 1996). A functional role
of the D4 receptor in the balance of excitatory and
inhibitory factors on pyramidal neurons in the primate
neocortex has thus been proposed. Moreover, the recent
finding that dopamine, epinephrine, and norepineph-
rine all show binding to recombinant human D4 recep-
tors in the nanomolar range, and that they activate
these receptors in vitro, has suggested a novel mecha-
nism for the integration of catecholamine signaling in
the brain (Lanau et al., 1997).
From the clinical point of view, the D4 receptor has
been attributed to involvement in the pathogenesis of
schizophrenia, since a group of atypical neuroleptics,
such as clozapine, has a high affinity for this dopamine
receptor subtype (Nestler, 1997; Seeman et al., 1997a;
Van Tol et al., 1992). It has been hypothesized that the
therapeutic properties of this drug are due to its action
on D4 receptors. When subtraction techniques with
ligands of different subtype binding profiles are used,
an increase in the density of D4 receptors is discovered
in the postmortem striatal tissue of patients suffering
from schizophrenia (Murray et al., 1995; Seeman et al.,
1993). Recently, a postmortem study using schizophre-
nia brain striata and [3H]GLC found increased levels of
a D2-like binding site not detected in control human
brains or Alzheimer’s, Huntington’s, or Parkinson’s
disease brains (Seeman et al., 1997b). This D2-like
binding site showed a receptor density (Bmax) of 6.6
pmol/g wet weight measured in the presence of drugs
which occluded the D1, D2, D3, and D5 receptors (See-
man et al., 1997b). However, the hypothesis that a
single dopamine receptor subtype such as the D4 recep-
tor may be a principal constituent in the pathogensis of
schizophrenia has been challenged by recent clinical
postmortem data (Helmeste et al., 1996; Kramer et al.,
1997; Lahti et al., 1996; Reynolds and Mason, 1995).
The present study investigated the distribution of the
D4 receptor under in vivo conditions in the nonhuman
primate brain on a macroscopic scale using the novel
dopaminergic radioligand [11C]GLC (Markstein et al.,
1996, Seeman et al., 1997b) and positron emission
tomography (PET). [11C]GLC, the chemical structure of
which is shown in Figure 1, has among all known
subtypes the highest affinity for D4-receptors (Table I).
The strategy was to quantify D4 receptors in the
presence of drugs that mask the D1, D2, D3, and D5
subtypes.
MATERIALS AND METHODS
Animal studies
PET studies were performed using healthy laboratory-
bred baboons (Papio hamadryas, one female and two
males, body weight 5–7 kg) obtained from the German
Primate Research Center in Go¨ttingen, Germany. All
study protocols were government-approved and corre-
sponded to the ethical codes and German legislation on
animal experiments. General anesthesia was induced
by an intramuscular injection of ketamine (10 mg/kg)
and maintained by a continuous infusion of methohexi-
tal (30–40 mg/kg/h). The intubated animals were venti-
Fig. 1. Chemical structure of SDZ GLC 756 (2)[(3R,4aR,10aR)-
1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-methyl-3-[(2-pyridyl-thio)-
methyl]-benzo[g]quinoline].
TABLE I. In vitro binding affinities (agonist or antagonist)
dissociation constants of different ligands to dopamine
receptor clones [nM]
D1 D5 D2 D3 D4
SDZ GLC 756 1.10a 6.03a 0.40b 25b 0.18a
SCH23390 0.37a 0.30a 634a 780a 3,000a
Raclopride 18,000a n.d. 1.80a 3.50a 1,500a
Spiperone 350a 3,500a 0.07a 0.60a 0.08a
n.d. 5 not determined.
aAntagonist binding.
bAgonist binding.
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lated with 100% O2 at an end tidal CO2 content of
35–38%. The noncentrally acting anticholinergic drug
glycopyrrolate (0.02 mg/kg) was given intravenously to
minimize salivation. A 20 gauge arterial catheter in-
serted into the femoral artery served for blood sampling
procedures. Another 20 gauge venous catheter placed in
the femoral vein of the opposite leg was used for the
application of the radiotracer, drugs, and fluids. In 1 of
12 experiments, two venous catheters were inserted
instead. The head of each baboon was positioned using
a specially designed head holder with an individual
polymer bed. Body temperature was kept constant at
37°C using a heating pad during the entire experiment.
Vital signs (heart rate, blood pressure, respiration rate,
oxygen saturation, expired carbon dioxide, and body
temperature) were continuously monitored.
Each baboon was subjected to four experimental
protocols (exp. 1 to exp. 4) at intervals of 7 days. During
each PET study, two intravenous slow bolus injections
(0.8 mCi/kg; injection time: 20–25 s) of [11C]GLC were
applied at an interval of 40–45 min, i.e., injection I and
injection II (Fig. 2). The first experiment was performed
without any receptor blockade. During the following
experiments (exp. 2 to exp. 4), dopamine receptor
antagonists were given intravenously 20 min prior to
injection II in doses sufficient to block the respective
receptors. SCH23390 (1.7 µmol/kg) was used to mask
D1 and D5 receptors (exp. 2). Blockade of D1, D2, D3, and
D5 receptors (exp. 3) was enabled using SCH23390 (1.7
µmol/kg) 1 raclopride (5.7 µmol/kg). A total blockade of
dopamine receptors, including the D4 subtype (exp. 4),
was achieved by the application of SCH23390 (1.7
µmol/kg) 1 raclopride (5.7 µmol/kg) 1 spiperone (2.5
µmol/kg). Raclopride tartrate was from Astra Arcus,
So¨derta¨llje, Sweden. Spiperone and SCH23390 were
purchased from Research Biochemicals International,
Biotrend, Cologne, Germany. Dynamic PET scans
started with the injection of [11C]GLC using a GE PC
4096 PLUS whole body PET camera (Rota Kops et al.,
1990). In the wobbled and interleaved mode, the resolu-
tion was 5.5 mm in the center field of view (interplane
distance of 3.2 mm). Iterative reconstruction resulted
in 30 slices and included corrections for attenuation,
scatter, random events, and deadtime. Images obtained
without previous receptor blockade were employed to
identify regions of interest (ROI). Orbito-meatal slices
were matched to a baboon brain atlas (Riche et al.,
1988) and square ROIs (9 3 9 mm) were placed to
encompass striatum, neocortex (frontal, temporal, pari-
etal, and occiptal), and cerebellum. In the double scan
protocol, the images from the first and second scan
sequences were in spatial register. Thus, identical ROIs
were placed on the first and second image sets from that
protocol.
Data analysis
For the two PET scans following injections I and II of
[11C]GLC, decay corrected time–activity curves were
constructed by plotting the percent injected dose per ml
of the tissue [%ID/ml] versus time p.i. The tissue
time–activity curves of the second PET scan following
injection II of [11C]GLC were corrected by the subtrac-
tion of the residual activity due to injection I using a
standardized curve-fitting procedure (Fig. 2). The proce-
dures for making such a correction were defined from
the extrapolation of the first scan sequences extended
to the end of the second scan sequence. It was found
that image intensity values during the period of inter-
est decreased time dependently with a good approxima-
tion to a monoexponential function (Fig. 2). Since
striatal, cortical, and cerebellar intensities decline with
different decay constants, a procedure was adopted in
which the respective decreasing regional intensity val-
ues observed in the first scan sequence were fitted by
least-square fitting to a monoexponential decay func-
tion of time (t):
f(t) 5 a(bt1c) (1)
The parameters a, b, and c were used to calculate the
regional intensity value from the first GLC injection
that would have been present at the given time during
the second scan sequence. This intensity value was
then reapplied as a subtractive correction to yield the
image intensities due to the second injection of [11C]GLC
(Fig. 2).
Specific binding (SB) of [11C]GLC[%ID/l] was defined
as the difference between cortical or striatal and cerebel-
lar [11C] concentration integrated between 10 and 60
Fig. 2. A representative PET experiment showing the concentra-
tion of [11C] in primate neocortex following two injections of [11C]GLC
(injection I: 4.75 mCi; injection II: 5.07 mCi). The present experimen-
tal protocol (exp. 1) reflects time–activity curves in the absence of cold
dopamine antagonists: (d) following injection I, raw data; (n) follow-
ing injection II, raw data; (h) following injection II, data corrected by
the subtraction of the residual radioactivity due to injection I. The
dotted lines depict the corresponding monoexponential fit (. . . . . . .)
and its extrapolation (.......).
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min p.i.: no receptor blockade (SBD1–D5); receptor block-
ade by SCH23390 (SBD2–D4); blockade of all non-D4
receptors by SCH23390 and raclopride (SBD4); blockade
of all known dopamine receptors by SCH23390, raclo-
pride, and spiperone, i.e., nonspecific binding of
[11C]GLC (NSB). Statistical analysis evaluating specific
and nonspecific binding of [11C]GLC during the various
blocking protocols was performed using the one-tailed
paired t-test. The significance level was set at P 5 0.05.
All sample data are presented as mean 6 standard
deviation (n 5 3).
Blood sampling and metabolite analysis
Arterial blood samples (0.5–1 ml) were collected
manually at intervals from 15 sec to 10 min up to 60
min p.i., diluted with the same amount of isopropanol,
and centrifuged at 2,000g for 3 min. Plasma radioactiv-
ity was measured using aliquots (50 µl) and a calibrated
automatic gamma counter (Wallac, 1480 Wizard 3).
Blood samples (taken from 15 sec to 20 min p.i.)
prepared for metabolite analysis by optimized radio
HPLC were taken using a Merck-Hitachi (L-6000)
pump and a Knauer UV/VIS filter photometer (9700)
with a detector wavelength of 254 nm. A sample injec-
tion was accomplished with a Rheodyne 7125 Injector
Block. To facilitate continuous measurement of radioac-
tivity, the UV detector outlet was connected to an
NaI(T1) well-type scintillation detector and the re-
corded data were processed by a software system
(Nuclear Interface, Datentechnik fu¨r Strahlungs-
meßgera¨te GmbH). For purposes of HPLC analysis,
aliquots of the supernatant blood plasma (500 µl) were
injected into the HPLC column (Kromasil C-18, 5 µm,
250 p 4 mm, equipped with a precolumn RP-18, 10 µm,
20 p 4 mm) and eluted with acetronitrile/0.025 M
aqueous diammonium hydrogen phosphate (55/45, v/v)
at a flow of 1 ml/min.
Synthesis of the radioligand
For intravenous application, [11C]GLC was synthe-
sized with a chemical and radiochemical purity of
.99% and a maximum specific activity of .29 TBq/
mmol: no carrier-added [11C]CF3SO3CH3 was produced,
according to a standard procedure (Holschbach and
Schu¨ller, 1993). The [11C]methyltriflate was carried by
helium into a reaction vial containing the desmethyl
precursor (0.2 mg, 0.6 µmol) in dry 1,2-dichloroethane
(500 µl). After 5 min reaction time at room temperature,
ethanol (2 ml) was added and the solution was injected
into a semipreparative HPLC. In order to circumvent
rotary evaporation of the eluent and in keeping with a
straightforward pharmaceutical formulation proce-
dure, the HPLC fraction containing the product was cut
out of the eluent flow and passed over a cation exchange
cartridge (Adsorbex SCX), conditioned before use with
HCl (0.1 N, 15 ml) and washed with water (5 ml),
NaHCO3 (0.1 N, 10 ml), and water (5 ml)). Elution of the
product through a 0.22 µm sterile filter into a sterile
vial was performed with ethanol (1 ml) followed by
physiological saline (9 ml). This procedure resulted in a
recovery of about 95% of the trapped radioactivity. The
specific activity of [11C]GLC was determined by HPLC
assay of an aliquot of the labeled product. The corre-
sponding signal was compared with a standard curve of
the UV absorption spectrum of the cold compound
recorded from a solution of a known concentration.
[11C]GLC and the desmethyl compound were provided
by Novartis Pharma AG, Switzerland.
RESULTS
The results depicted in Figure 3A reflect [11C]GLC
binding to all dopamine receptor subtypes as well as
nonspecific [11C]GLC binding. [11C]GLC binding was
high in striatum and moderate in neocortical regions.
Due to the blockade of D1 and D5 receptors by SCH23390
(Fig. 3B), the accumulation of [11C]GLC was markedly
reduced in the striatum, while binding in the neocortex
declined only slightly. Blockade of all non-D4 receptors
by SCH23390 and raclopride resulted in a homoge-
neous and low accumulation of [11C]GLC in striatum
and in frontal, temporal, parietal, and occipital cortex
(Fig. 3C). Following the combined use of SCH23390,
raclopride, and spiperone, the binding of [11C]GLC was
reduced to the nonspecific level (Fig. 3D).
Time–activity curves (Fig. 4) showed a high accumu-
lation and a relatively slow washout of [11C]GLC in the
striatum, a region of brain with a dense dopaminergic
innervation. In the striatum, the concentration of [11C]
reached a peak at 35% ID/l within the first 5 min p.i.
During this time, the radioactivity concentration of the
cerebellum reached a peak of 30% ID/l, which slightly
exceeded that of the neocortex (displayed as mean of
frontal, temporal, parietal, and occipital ROIs). In the
striatum and neocortex, the time–activity curve de-
creases reflected the blockade of distinct receptor popu-
lations due to the application of cold dopamine antago-
nists (exp. 2 to exp. 4). The cerebellar concentration of
[11C] used here as a region of nonspecific binding was
not influenced by the different blocking procedures. The
curves showing the difference of regional striatal/
neocortical and cerebellar radioactivity (Fig. 5) reached
a peak at 15 to 20 min p.i. Differences between the
Fig. 3. Example of differential dopamine-receptor-subtype map-
ping in a baboon brain with [11C]GLC. Coronal and saggital planes are
cut through the anterior portion of the left striatum (slice thickness:
3.2 mm; integration time: 10 to 60 min after injection). The [11C]GLC
concentration is normalized to the injected dose and to the highest
regional uptake in the unblocked state (set to 1.0, linear scale)
observed in the striatum. Binding of [11C]GLC in the unblocked state
(A) and following the intravenous application of dopamine receptor
antagonists 20 min prior to the injection of [11C]GLC, i.e., SCH23390
(B), SCH23390 1 raclopride (C) and SCH23390 1 raclopride 1
spiperone (D).
344 C. BOY ET AL.
Fig. 3
345IMAGING DOPAMINE D4 RECEPTORS
curves reflected the reductions of specific binding caused
by the fractionated blockade of dopamine receptor
subtypes.
Figure 6 summarizes the regional specific binding
(SB) of [11C]GLC in the course of the differential
dopamine receptor mapping approach. The statistical
evaluation of differences of means between the different
experiments is given in Table II. In the unblocked state
(exp. 1), SBD1–D5 [%ID/l] in striatum (150.2 6 27.9) was
about six times higher than in frontal (25.0 6 3.1),
temporal (24.7 6 3.1), parietal (24.8 6 3.3), and occipi-
tal neocortex (26.6 6 2.2). Following the application of
SCH23390, SB was reduced by 55 6 4% in the striatum
(SBD2–D4 vs. SBD1–D5, P , 0.05). In the neocortex, the
reduction of SB reached statistical significance in the
frontal ROIs (213 6 8%, SBD2–D4 vs. SBD1–D5, P , 0.05).
The binding difference of [11C]GLC between exp. 2 and
exp. 3 due to the application of SCH23390 and raclo-
pride mirrored the presence of D2 and D3 dopamine
receptors in the striatum (SBD4 vs. SBD2–D4, P , 0.05).
SB of [11C]GLC to D4 receptors [%ID/l] was found in
frontal (18.4 6 5.5), temporal (19.2 6 5.3), parietal
(18.4 6 6.0), and occipital neocortex (19.3 6 5.5), as
well as within the striatum (20.0 6 11.0). The differ-
ences between exp. 3 and exp. 4 (SBD4 vs. NSB)
revealed the presence of D4 receptors since [11C]GLC
binding decreased significantly in striatal and in
all neocortical regions. In the striatum, SBD4/SBD1–5,
the ratio of SB of [11C]GLC to D4 receptors (exp. 3)
and the SB to all dopamine receptor subtypes (exp. 1)
was 0.13 6 0.07. In the neocortex, SBD4/SBD1–5
was notably higher (0.77 6 0.29; mean of all cortical
ROIs).
There was a rapid clearance of [11C]GLC from the
blood, reaching values of ,0.015% ID/ml at 10 min p.i.
(Fig. 7). Figure 8 displays the chromatogram of a
representative arterial blood sample obtained 2.25 min
after the injection of [11C]GLC. Metabolites of [11C]GLC
generated two major peaks and were not expected to
pass the blood–brain barrier because of abundant polar
groups. The fraction of nonmetabolized [11C]GLC in the
arterial plasma compartment (Fig. 9) at 1, 2, 5, and 10
min after injection was 42.3, 24.9, 15.5, and 9.5%,
respectively. The HPLC results using probes obtained
after the application of SCH23390 and raclopride (exp.
3) or using venous blood sampling were in the same
range (Fig. 9).
DISCUSSION
For five years following the cloning of D4 receptor
(Van Tol et al., 1992), the low level of D4 expression in
brain tissue together with the lack of a D4 receptor-
specific ligand made the localization and physiological
characterization of this dopamine receptor particularly
difficult. For example, in postmortem striatum from
healthy human subjects the density of D4 receptors was
reported in the range of 2.1 to 5.2 pmol/g wet weight
(Seeman et al., 1993, 1995) or about 40 pmol/g protein
weight (Murray et al., 1995). In the basal ganglia of the
healthy rat, a Bmax of 6.4 pmol/g wet weight was
Fig. 4. Time course of [11C] concentration in different regions of
primate brain after the i.v. injection of [11C]GLC (0.8 mCi/kg). Curves
reflect the unblocked state (s) and the reductions of regional [11C]
concentration due to the i.v. application of SCH23390 (‘), SCH23390
and raclopride (n), SCH23390, raclopride, and spiperone (,). For the
interval of 10–60 min p.i., data normalized to the injected dose per
volume [%ID/l] are presented as mean 6 standard deviation, n 5 3; (A)
striatum; (B) neocortex, mean of frontal, temporal; parietal, and
occipital; (C) cerebellum.
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detected (Schoots et al., 1995). Our investigation, which
used [11C]GLC and PET, is providing the first in vivo
evidence of a widespread distribution of dopamine D4
receptors in striatum and neocortex in the brain of the
healthy primate.
The mapping approach of D4 receptors taken in the
present study is unlikely to be significantly influenced
by [11C]GLC binding to non-D4 dopamine- or non-
dopamine receptors for a number of reasons:
First, the blockades of dopamine receptors by
SCH23390, raclopride, and spiperone are highly spe-
cific. These receptor antagonists bind with nanomolar
affinities to the dopamine receptor subtypes (Table I).
Second, the blockade of non-D4 dopamine receptors was
achieved using SCH23390 and raclopride in doses of
up to two orders of magnitude above those shown to
block the respective receptors (Farde et al., 1992).
According to PET studies on healthy human subjects,
a single intravenous dose of 0.42 to 0.81 mg SCH23390
per patient could be related to a D1 receptor occu-
pancy of up to 59%. The injection of 0.2 to 0.5 mg
raclopride per patient gave a brain D2 receptor
occupancy of up to 73%. Such data, therefore, suggest
that an adequate occupancy of the receptors on the
basis of the blocking procedures used can be as-
sumed.
Third, binding of [11C]GLC to non-dopamine receptors,
which would bias the measurement of D4 receptors, is
not likely since spiperone—under the experimental
protocol invoked here to block D4 receptors—does not
bind with high affinity to receptors such as 5HT,
adrenergic, cholinergic, or sigma receptors (Waeber
et al., 1988; Hoyer, 1991; Goffinet et al., 1990; Ford et
al., 1994; Roth et al., 1995).
In the present investigation, dopamine D4 receptors
were found in the cortical and subcortical regions
known to receive dopaminergic input: dopamine neu-
rons of the ventral mesencephalon designated as A8,
A9, and A10 cell groups project into the striatum, the
limbic system, and also extensively into the cortex—
Fig. 5. Difference of striatal or neocortical and cerebellar [11C]
concentration as a function of time after the injection of [11C]GLC in
the unblocked state (s) and following the application of SCH23390
(‘), SCH23390 and raclopride (n), or SCH23390, raclopride, and
spiperone (,). For the interval of 10–60 min p.i., data normalized to
the injected dose per volume [%ID/l] are presented as mean 6
standard deviation, n 5 3. (A) striatum; (B–D) neocortex: mean of
frontal, temporal, parietal, and occipital.
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especially the prefrontal and cingulate cortices (Bjork-
lund and Lindvall, 1984; Berger et al., 1991). The
present D4 receptor distribution revealed by [11C]GLC
is consistent with both the distribution pattern of D4
receptor-coding mRNA and the distribution of the en-
coded receptor protein in the brains of nonhuman
primates. First, high levels of D4-coding mRNA have
been detected in frontal cortex, midbrain, medulla, and
amygdala and lower concentrations have been reported
for striatum and hippocampus, whereas none was
found within the cerebellum (Van Tol et al., 1992).
Second, D4-immunoreactive neurons have been local-
ized in frontal, temporal, and parietal neocortex, in the
globus pallidus and—showing low staining—in caudate
nucleus and putamen (Mrzljak et al., 1996).
Fig. 6. Specific binding (SB) of [11C]GLC defined as the difference
regional and cerebellar uptake integrated between 10 and 60 min after
injection [%ID/l]. Columns indicate SB during progressive blockade of
dopamine receptors 20 min before the injection of [11C]GLC: (1)
SBD1-D5, no receptor blockade; (2) SBD2-D4, receptor blockade by
SCH23390; (3) SBD4, blockade of all non-D4-receptors by SCH23390
and raclopride; (4) NSB, blockade of all known dopamine receptors by
SCH23390, raclopride, and spiperone (mean 6 standard deviation,
n 5 3).
TABLE II. Statistical analysis evaluating the differences of the
specific binding of [11C]GLC due to the application of different
dopamine receptor antagonists
Exp. 2 vs. exp. 1 Exp. 3 vs. exp. 2 Exp. 4 vs. exp. 3
Striatum 0.01 0.01 0.04
Frontal ctx 0.05 0.29 0.01
Temporal ctx 0.13 0.46 0.01
Parietal ctx 0.18 0.38 0.01
Occipital ctx 0.18 0.38 0.01
As displayed in Figure 6 with P-values of obtained from the one-tailed paired
t-test; n 5 3. Exp. 5 experiment; ctx 5 cortex.
Fig. 7. Representative arterial plasma concentration of [11C] follow-
ing the injection of 0.8 mCi [11C]GLC per kg body weight [%ID/l]
(mean 6 standard deviation, n 5 3).
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In conclusion, [11C]GLC is a candidate PET ligand for
the in vivo investigation of D4 receptors or D4-like
binding sites in basic science and clinical protocols. The
widespread distribution of D4 receptors in primate
neocortex suggests that among the relatively few corti-
cal dopamine receptors, this receptor subtype consti-
tutes a significant proportion and may play a major role
in catecholaminergic modulation of neuronal activity in
primate neocortex.
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